GLPwatch
Trials (2167)
Page 13 of 37.
- STEP TEENS Weight Maintenance: A Research Study on How Well Semaglutide Helps Teenagers With Excess Body Weight to Lose Weight and Maintain Weight Loss
- Investigation on Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of Multiple Doses of a Long-acting GLP-1 Analogue in Healthy Male Subjects and Male Subjects With Type 2 Diabetes
- Ultrasound of the Knee in Obese Patients With Knee Osteoarthritis; Weight Loss
- A Study of LY3305677 in Participants With Obesity Or Overweight
- Investigation of Gastric Emptying by Gastric Ultrasonography in Diabetic Patients Treated With GLP-1 Receptors
- Acute Subcutaneous SemaglutidE in Acute Ischemic sTroke
- Adding Liraglutide to High Dose Insulin: Breaking the Cycle
- Effects of Tirzepatide Plus Intensive Lifestyle Therapy on Body Weight and Metabolic Health in Latinos With Obesity
- Evaluation of Liraglutide 3.0mg in Patients With Poor Weight-loss and a Suboptimal Glucagon-like Peptide-1 Response
- GLP-1 Agonists for Lung Function Improvement and Muscle Restoration in COPD
- Effects of LY2189265 on Glycemic Control in Participants With Type 2 Diabetes
- Probiotic Intervention for Digestive Health in Obese Patients Initiating GLP-RA Treatment
- Investigating the Influence of Oral Semaglutide on Pharmacokinetics of Metformin and Digoxin in Healthy Subjects
- Safety and Tolerability of Liraglutide in Healthy Volunteers and Subjects With Type 2 Diabetes
- A Long-Term Study of Tirzepatide (LY3298176) in Adults With Type 1 Diabetes and Obesity or Overweight
- This is a Study to Evaluate the Pharmacokinetics and Safety of IBI362 in Chinese Adolescents With Obesity
- A Research Study Looking at How Cagrilintide Works on the Heart Rhythm in Healthy Participants
- INSPIRE Turkey :A Research Study Looking at the Clinical Parameters Associated With Use and Discontinuation of Saxenda® in Local Clinical Practice in Turkey by Analysing Past Patient Medical Records
- A Research Study Comparing How Well Different Doses of the Medicine NNC0662-0419 Lower Blood Sugar in People With Type 2 Diabetes
- Gastric Emptying in Healthy Volunteers and GLP-1 Agonist Users
- Dulaglutide Versus Liraglutide in Obese Type 2 Diabetic Adolescents Using Metformin
- Short Term Weight Loss With Liraglutide and Metformin in Infertile Obese PCOS Patients
- Type II Diabetes Mellitus in Patients Exposed to Pravastatin and Paroxetine
- A Clinical Trial Comparing Efficacy and Safety of Insulin Degludec/Liraglutide (IDegLira) Versus Basal-bolus Therapy in Subjects With Type 2 Diabetes Mellitus
- Effect of Semaglutide in Patients With Psoriasis and Obesity
- Incretin and Treatment With Inhibition of Sodium-glucose Cotransporter-2 Combination Insights Into Mechanisms Implicated in Congestive Heart Failure: "NATRIURETIC" Trial
- Efficacy and Safety of Semaglutide Once-weekly Versus Sitagliptin Once-daily as add-on to Metformin in Subjects With Type 2 Diabetes (SUSTAIN - CHINA MRCT)
- A Study of a Novel Precision Medicine Approach For Obesity
- Perioperative Stress Hyperglycemia in General and Vascular Surgery Patients
- A Multiple Dose Study of LY3502970 in Healthy Overweight and Obese Participants
- The Effect and the Pharmacogenomics Study of Liraglutide in Obese Patients
- A Research Study to Find Out How Semaglutide Works in the Kidneys Compared to Placebo, in People With Type 2 Diabetes and Chronic Kidney Disease (the REMODEL Trial)
- Effects of RDX-002 on Postprandial Triglycerides in Patients Discontinuing GLP-1 Agonists
- Tirzepatide in PWS, HO and GNSO
- A Study Comparing the Dulaglutide Pen and the Semaglutide Pen
- A Trial Investigating the Influence of Oral Semaglutide on Pharmacokinetics of Ethinylestradiol and Levonorgestrel in an Oral Contraceptive Combination Drug in Healthy Postmenopausal Females
- Effects of Semaglutide on Nicotine Intake
- A Study of LY3502970 in Participants With Impaired and Normal Liver Function
- Investigation of Safety and Efficacy of Once-daily Semaglutide in Obese Subjects Without Diabetes Mellitus
- A Trial Within Cohort Feasibility Study Design Comparing Standard of Care Versus Weight Loss (Achieved Through Tirzepatide) for Obesity-related Hypertension in Young Adults
- Loxenatide Plus LNG-IUS in Endometrial Atypical Hyperplasia
- Pharmacokinetics of IBI362 in Subjects With and Without Renal Impairment
- Genetics of the Acute Response to Oral Semaglutide
- Post-marketing Surveillance (Special Use-results Surveillance) on Use With Liraglutide (Victoza®)
- Feasibility of Once/Daily Administered GLP/1 Receptoragonist (Lixisenatide) in Combination With Basal Insulin
- Semaglutide and Structured Lifestyle Support to Improve Heart and Blood Vessel Health in Postmenopausal Obese Breast Cancer Survivors Taking Aromatase Inhibitors
- The Effect of Insulin Degludec in Combination With Liraglutide and Metformin in Subjects With Type 2 Diabetes Qualifying for Treatment Intensification
- GLP-1 Agonism for Blocking Cocaine Euphoria and Self-Administration
- Effect of Itopride on Semaglutide Gastroparesis
- A Research Study Looking at Blood Sugar Control in People With Type 2 Diabetes Previously Treated With Premix Insulin and Initiating Treatment With Insulin Degludec/Liraglutide (IDegLira) in Local Clinical Practice in Croatia
- Effects of GLP1-RA on Ectopic Fat Deposition in Chronic Kidney Disease
- Evaluating Liraglutide in Alzheimer's Disease
- Treatment of Antipsychotic-associated Obesity With a GLP-1 Analogue
- A Study of LY3502970 in Chinese Participants With Obesity or Are Overweight With Weight-related Comorbidities
- Glycaemic Control of Weekly LAPS-Exendin Versus Placebo in Subjects of Type 2 Diabetes
- Effect of Liraglutide in Obese Subjects With Moderate or Severe Obstructive Sleep Apnoea: SCALE™ - Sleep Apnoea
- Effect and Safety of Liraglutide 3.0 mg in Subjects With Overweight or Obesity and Type 2 Diabetes Mellitus Treated With Basal Insulin
- Real-world Health Outcomes in Canadian Patients Using Semaglutide
- A Trial Investigating the Effect of Probenecid and Ciclosporin on the Concentrations of SNAC in Healthy Subjects
- A Study of Dulaglutide (LY2189265) 3.0 mg and 4.5 mg in Pediatric Participants With Type 2 Diabetes Mellitus (AWARD-PEDS PLUS)